Nucleoside analogue switch

PreclinicalSmall molecule

NNorthwestern University

Nucleoside analogue switch is one of 35 small molecule programs targeting Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Atrophy

#DrugCompanyPhaseTrials

Evrysdi

Actos

1 3

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 4

Activella

Eli Lilly

Phase 3

1 5

Pitocin

RRetrophin

Phase 3

4 6

Avandia

Alnylam Pharmaceuticals

Phase 2

1 7

Protease Inhibitors

Tibotec Pharmaceuticals, Ireland

Approved

1 8

Protease Inhibitor

MMedical Research Council

Approved

1 9

Prometrium

Ferring

Phase 2

1 10

Avodart

Akero Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Completed·NNorthwestern University··NCT00225082·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nucleoside analogue switch. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nucleoside analogue switch compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nucleoside analogue switch. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthwestern University

Nucleoside analogue switch

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy1 trial

References

Drug Info

Quick Facts

Related News